Cannabidiol-Based Thiosemicarbazones: A Preliminary Study Evaluating Their Anti-Tyrosinase Properties
Molecules · 2025
DOI: 10.3390/molecules30061291 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Eliav Peretz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, Tel-Hai Academic College, Kiryat Shmona 11016, Israel. Hauptthemen laut MEDLINE: Monophenol Monooxygenase, Thiosemicarbazones, Cannabidiol, Enzyme Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Migal-Galilee Research Institute, the Council for Higher Education of Israel.
Abstract (Originalsprache)
Cannabidiol (CBD), a non-psychoactive cannabinoid, has attracted significant research interest due to its antioxidant, anti-inflammatory, and neuroprotective properties. As a versatile scaffold in drug discovery, CBD has been widely explored for developing novel therapeutics. In this study, we synthesized and evaluated the anti-tyrosinase activity of CBD-based thiosemicarbazones. Structure–activity relationship (SAR) analyses were conducted to assess the impact of various functional groups on tyrosinase inhibition, including an evaluation of inhibitory kinetics for selected compounds. The synthesized derivatives demonstrated potent tyrosinase inhibition, with activity comparable to kojic acid, a standard tyrosinase inhibitor. Given the crucial role of tyrosinase in melanin biosynthesis, these findings suggest that CBD-based thiosemicarbazones could serve as promising candidates for managing tyrosinase-related disorders, including hyperpigmentation and melanogenesis-related conditions. Moreover, the presence of thiosemicarbazone moieties may contribute to the observed inhibitory effects, potentially through metal chelation at the enzyme’s active site. This study provides valuable insights into the design of CBD-derived inhibitors targeting tyrosinase. Further optimization and in-depth biological evaluation are warranted to explore their full therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, Tel-Hai Academic College, Kiryat Shmona 11016, Israel.
- Natural Compounds and Organic Synthesis Laboratory, Migal-Galilee Research Institute, Kiryat Shmona 11016, Israel.
ORCID-Profile: Sanaa Musa
Förderung
- Migal-Galilee Research Institute
- the Council for Higher Education of Israel
Zitieren
APA
Peretz, E., Ashkenazi, N., & Musa, S. (2025). Cannabidiol-Based Thiosemicarbazones: A Preliminary Study Evaluating Their Anti-Tyrosinase Properties. Molecules. https://doi.org/10.3390/molecules30061291
Vancouver
Peretz E, Ashkenazi N, Musa S. Cannabidiol-Based Thiosemicarbazones: A Preliminary Study Evaluating Their Anti-Tyrosinase Properties. Molecules. 2025. doi:10.3390/molecules30061291
BibTeX
@article{Peretz2025,
author = {Peretz, Eliav and Ashkenazi, Noa and Musa, Sanaa},
title = {Cannabidiol-Based Thiosemicarbazones: A Preliminary Study Evaluating Their Anti-Tyrosinase Properties},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30061291}
}
EUVIMED